Member Login
Home
About Us
Officers
Contact Us
Corporate Members
Become a Corporate Member
Events
2024 Annual Meeting Attendee Info
2024 Annual Meeting Exhibitors
2024 Abstracts
2024 ASCO Direct
Past Annual Meeting Highlights
Membership
Resources
Job Bank
Advertise a Job
FDA Approvals
Podcasts
Find an Oncologist
Useful Links
Corporate Members
FDA Approvals
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
Now Approved
Breyanzi®—a CAR T cell therapy option for patients with R/R CLL or SLL2
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
DARZALEX
FASPRO
® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible
FDA has approved BOSULIF (bosutinib) for a new indication and has also approved a new formulation.
Home
About Us
Officers
Contact Us
Corporate Members
Become a Corporate Member
Events
2024 Annual Meeting Attendee Info
2024 Annual Meeting Exhibitors
2024 Abstracts
2024 ASCO Direct
Past Annual Meeting Highlights
Membership
Resources
Job Bank
Advertise a Job
FDA Approvals
Podcasts
Find an Oncologist
Useful Links
Pennsylvania Society of Oncology and Hematology